NCT05567887View on ClinicalTrials.gov

A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies

PHASE1CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

November 2, 2022

Primary Completion Date

October 2, 2024

Study Completion Date

October 2, 2024

Conditions
LymphomaMultiple Myeloma
Interventions
DRUG

maplirpacept (PF-07901801)

maplirpacept (PF-07901801)

Trial Locations (4)

466-8650

Japanese Red Cross Aichi Medical Center Nagoya Daini Hospital, Nagoya

135-8550

Japanese Foundation for Cancer Research, Koto

The Cancer Institute Hospital of JFCR, Koto

990-9585

Yamagata University Hospital, Yamagata

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05567887 - A Study to Learn About the Study Medicine (Called Maplirpacept (PF-07901801)) in Japanese With Hematologic Malignancies | Biotech Hunter | Biotech Hunter